Amiselimod

• UNSPSC Description:

  Amiselimod (MT-1303) is a modulator for sphingosine 1-phosphate receptor (S1P receptor). Amiselimod converses to its active metabolite (S)-amiselimod phosphate by sphingosine kinases (SPHKs), targets S1P1 receptor, ameliorates the autoimmune disease without causing bradycardia[1].

• Target Antigen:

  LPL Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/amiselimod.html

• Smiles:

  FC(F)(C1=CC(CCC(CO)(CO)N)=CC=C1OCCCCCCC)F

• Molecular Weight:

  377.44

• References & Citations:

  [1]Sugahara K, et al., Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15-27.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  942399-20-4